Navigating the MFN Landscape
Global Commercialization in an MFN World
What biotech leaders need
to know about MFN
Most-Favored-Nation (MFN) drug pricing has created understandable concern for some biotech companies preparing to commercialize globally. For the first time, U.S. drug prices are no longer insulated from international markets. Pricing decisions made abroad now have the potential to directly influence the economics of the U.S. market.
For some biotechs, the initial reaction might be to “pause and wait.” Such a decision is costly and based on an incomplete view of how MFN works. Biotech leaders need to understand the fundamental realities of MFN:
Impact is
concentrated
Direct MFN exposure is limited to a defined set of 19 reference countries, not the full global market, meaning most international launches carry no direct risk to U.S. pricing. Notably, only five of those reference countries fall outside of the U.S., Western Europe, and Japan.
Most markets remain unaffected
A large portion of global revenue opportunity remains fully and immediately accessible, with dozens of non-referenced markets posing no MFN risk.
Even referenced markets are not off-limits
The right go-to-market approach enables companies to retain governance over pricing decisions and launch timing in MFN-referenced markets to protect U.S. pricing.
Biotechs do not need to delay global commercialization.
They need to know where to maintain tighter governance, where to move faster, and how to avoid commercialization models that create unnecessary exposure.
Medison helps biotechs navigate MFN complexity
Be in the driver’s seat. Retain governance over pricing decisions in MFN-referenced markets.
Medison enables biotechs to maintain governance in a way that ex-U.S. licensing models do not. In MFN-referenced markets, the biotech partners determine the pricing strategy and sequence.
Unlock value and accelerate time to market in non-MFN referenced markets.
Across Medison’s international scope, most countries are not referenced markets under MFN guidelines. Treat patients in dozens of countries and unlock value without MFN risk
One accountable global partner.
Medison provides centralized execution, visibility, and pricing governance across international markets.
Navigating the MFN Landscape
Get the breakdown of how MFN works, where impact truly exists, and how biotechs can keep moving globally without endangering U.S. pricing.